Business
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
SHANGHAI & CAMBRIDGE, Mass., September 02, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/12a13625be0aa51d1ed540c4e02e2832"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WRrq5kgQijjbW6fjloX8mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/12a13625be0aa51d1ed540c4e02e2832","width":480,"height":224}},"lazy":false},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., September 02, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.","length":353,"tagName":"p"},{"type":"text","content":""Today’s approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China," said Andrew Zhu, Chief Commercial Officer, Greater China, Zai Lab. "Treatment options for patients with recurrent or metastatic cervical cancer after initial therapy are limited. TIVDAK, the first antibody-drug conjugate (ADC) therapy in cervical cancer, delivers a clinically meaningful survival benefit to patients. With our established commercial infrastructure for ZEJULA in Hong Kong, we are uniquely positioned to ensure TIVDAK reaches patients without delay."","length":619,"tagName":"p"},{"type":"text","content":"TIVDAK is currently under regulatory review for its Biologics License Application by China’s National Medical Products Administration (NMPA), which was accepted in March 2025.","length":175,"tagName":"p"},{"type":"text","content":"About TIVDAK® (tisotumab vedotin-tftv)","length":38,"tagName":"p"},{"type":"text","content":"TIVDAK® (tisotumab vedotin) is an ADC composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Pfizer’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. Nonclinical data suggest that the anticancer activity of tisotumab vedotin is due to the binding of the ADC to TF-expressing cancer cells, followed by internalizati...